{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:00:42Z","timestamp":1768712442276,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.dsx.2021.102207","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T12:13:47Z","timestamp":1626092027000},"page":"102207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3353-8865","authenticated-orcid":false,"given":"Hind B.","family":"Almufty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinah A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muayad A.","family":"Merza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dsx.2021.102207_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dsx.2021.102207_bib2","article-title":"COVID-19 Vaccine: a comprehensive status report","author":"Gupta","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.dsx.2021.102207_bib3","series-title":"Status of COVID-19 vaccines within WHO EUL\/PQ evaluation process. Geneva, Switzerland","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.dsx.2021.102207_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2021.102207_bib5","series-title":"Systemic reactions, adverse events, and Serious adverse events: Pfizer-BioNTech COVID-19 vaccine","author":"Local Reactions","year":"2021"},{"issue":"2","key":"10.1016\/j.dsx.2021.102207_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dsx.2021.102207_bib7","series-title":"WHO target product profiles for COVID-19 vaccines. Version 3-29","author":"World Helath Organization","year":"2020"},{"issue":"4","key":"10.1016\/j.dsx.2021.102207_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10654-020-00634-3","article-title":"Vaccine confidence in the time of COVID-19","volume":"35","author":"Wu","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.dsx.2021.102207_bib9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10654-020-00671-y","article-title":"Vaccine hesitancy: the next challenge in the fight against COVID-19","volume":"35","author":"Dror","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.dsx.2021.102207_bib10","series-title":"Epidemiological Trends of coronavirus disease 2019 in Iraqi Kurdistan. Disaster medicine and public health Preparedness","first-page":"1","author":"Merza","year":"2021"},{"key":"10.1016\/j.dsx.2021.102207_bib11","series-title":"WHO confirms the safety and efficacy of COVID-19 vaccines and urges Iraqis to register and vaccinate to help defeat the pandemic","author":"World Health Organization","year":"2021"},{"issue":"18","key":"10.1016\/j.dsx.2021.102207_bib12","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.vaccine.2019.03.041","article-title":"Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument","volume":"37","author":"Luyten","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.dsx.2021.102207_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/vaccines9030218","article-title":"Attitude and behaviors towards SARS-CoV-2 vaccination among healthcare workers: a cross-sectional study from Poland","volume":"9","author":"Szmyd","year":"2021","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.dsx.2021.102207_bib14","first-page":"1428","article-title":"Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech republic","volume":"10","author":"Riad","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.dsx.2021.102207_bib15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dsx.2021.102207_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2021.102207_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dsx.2021.102207_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijwd.2021.01.007","article-title":"The art of prevention: COVID-19 vaccine preparedness for the dermatologist","author":"Rice","year":"2021","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"3","key":"10.1016\/j.dsx.2021.102207_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.dsx.2021.102207_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3947\/ic.2021.0302","article-title":"COVID-19 vaccination for people with comorbidities","volume":"53","author":"Choi","year":"2021","journal-title":"Infect Chemother"},{"issue":"6","key":"10.1016\/j.dsx.2021.102207_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/vaccines9060556","article-title":"Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects","volume":"9","author":"Hatmal","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.dsx.2021.102207_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/life11030249","article-title":"Self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey","volume":"11","author":"Mathioudakis","year":"2021","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.dsx.2021.102207_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1538-7836.2007.02328.x","article-title":"Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review","volume":"5","author":"Di Nisio","year":"2007","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"7852","key":"10.1016\/j.dsx.2021.102207_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41586-021-00785-7","article-title":"What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine","volume":"592","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2021.102207_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: communication from the ISTH SSC Subcommittee on Platelet Immunology","author":"Nazy","year":"2021","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.dsx.2021.102207_bib26","series-title":"A\u00a0prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination","author":"Greinacher","year":"2021"},{"key":"10.1016\/j.dsx.2021.102207_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination","author":"Lee","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121002277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:16:16Z","timestamp":1761729376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121002277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1871402121002277"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102207","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102207"}}